SCATTERED MEMORIES:

Memory Loss and Other Side Effects Fuel the Statin Debate

DIAMONDS: A Sperm’s Best Friend?
The High Price of DIABETES
Keeping Your Patients’ ELECTRONIC DATA SAFE
**Victoza® vs sitagliptin—dig deeper into the differences.**

Victoza® works like natural GLP-1 to treat type 2 diabetes.1

After 52 weeks—

**Greater HbA1c reductions vs sitagliptin**

1.3% with Victoza® 1.2 mg to 1.5% vs sitagliptin 100 mg†

**Greater weight reductions vs sitagliptin**

2.8 kg with Victoza® 1.2 mg to 3.7 kg vs sitagliptin 100 mg†

---

*More than 600,000 patients worldwide have been prescribed Victoza®.3*

---

1. Victoza® 1.2 mg = metformin (n=155); Victoza® 1.8 mg = metformin (n=176); vs sitagliptin 100 mg = metformin (n=166) over 52 weeks.


3. Internal calculations based on IMS Midas Quantum data, May 2012.

---

**References:**


---

**Prescribing information**

Victoza® 6 mg/ml solution for injection in pre-filled pen

1. 1 ml of solution contains 6 mg of liraglutide.

2. **Indication:** Treatment of adults with type 2 diabetes mellitus in combination with metformin or a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of metformin or sulphonylurea monotherapy, or in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione in patients with insufficient glycaemic control despite dual therapy.

3. **Dosage:** Victoza® is administered once daily by subcutaneous injection and at any time within a meal or 2 hours after the meal.

4. **Starting dose:** For patients without a history of pancreatitis, the starting dose is 0.6 mg once daily; for patients with a history of pancreatitis, the starting dose is 0.12 mg once daily.

5. **Dose adjustment:** After at least one week, the dose should be increased to a maintenance dose of 1.2 mg. Based on clinical response, after at least one week the dose can be increased to 1.8 mg. Daily doses higher than 1.8 mg are not recommended. When added to existing sulphonylurea or in combination with metformin and a sulphonylurea, a reduction in the dose of sulphonylurea may be necessary to reduce the risk of hypoglycaemia.

6. **Contraindications:** Contraindications to liraglutide include patients with a history of pancreatitis, allergic reactions to liraglutide or any of its excipients, and patients with certain medical conditions such as inflammatory bowel disease and pancreatitis.

---

**Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.**

---

**Victoza® and the APS bull are trademarks owned by Novo Nordisk A/S.**

---

**Novo Nordisk is changing diabetes. We provide innovative treatment solutions that empower people to achieve and maintain good control of their diabetes.**
NEW ORLEANS 2013

HYATT REGENCY NEW ORLEANS

SEPTEMBER 24–28, 2013

REGISTER TODAY

SEPTEMBER 24-25, 2013

Take your exam with confidence! Whether you are seeking initial certification or recertification, the Society’s Endocrine Board Reviews are the premier preparatory courses for you. Get real-time feedback on your performance with these interactive mock-exams.

REGISTER BY AUGUST 22 FOR DISCOUNTED RATES.
Visit us online or call Society Services at 1.888.363.6762 (toll free in the US) or 1.301.941.0210.

LEARN MORE AT WWW.ENDO-SOCIETY.ORG/NOLA!

SEPTEMBER 26-28, 2013

CLINICAL ENDOCRINOLOGY UPDATE

Attend the 65th CEU to get the most recent updates from across the entire field of endocrinology. Get the information you need in the smaller interactive format that you enjoy.
The Ambassador Exchange Program is an international exchange program aimed at establishing collaborative relationships between leading U.S. medical centers and international medical centers serving indigent populations. A two-person team from each participating institution (an established endocrinologist and a trainee) will be selected to represent their institution in the exchange.

- Each exchange lasts up to two weeks
- The U.S. participants travel first to the international medical center
- The international medical center participants will finalize their visit to the U.S. center by attending The Endocrine Society’s annual meeting, if possible
- Travel expenses (airfare, lodging, meals, and local transportation) are covered by The Endocrine Society

THE ENDOCRINE SOCIETY IS ACCEPTING APPLICATIONS FOR THE 2014 AMBASSADOR EXCHANGE PROGRAM.

To apply or for more information on the program, visit www.endocrine.org/international/ambassador-exchange-program.cfm

© 2013 The Endocrine Society

Clinical Answers. Stat.

UpToDate MobileComplete™
GET IT NOW.

UpToDate MobileComplete is now available for iPhone, iPad and Android™ devices!*

Our highly-rated Mobile Apps offer powerful features such as persistent login, bookmarks, auto-complete search, history and mobile-optimized calculators.

Upgrade your individual subscription by adding MobileComplete and:
- Get the fastest version of UpToDate® on your smartphone or tablet.
- Use UpToDate without an Internet connection¹ — even in dead zones!
- Reduce data usage if you have a limited data plan.

Subscribe to UpToDate and get MobileComplete on your smartphone or tablet today! Go to learn.uptodate.com/MC or call 1-888-525-1299 to order.

* iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google Inc.
1. Wi-Fi access is required for initial UpToDate MobileComplete download and full content updates.
Stay Current with New Endocrine Self-Assessment Tools

Whether you’re looking for the latest information from the experts or in need of MOC points, *ESAP™ 2013* and *Pediatric ESAP 2013-2014* are the smart choices to improve your clinical knowledge.

- Two online modules available, each featuring 50 questions covering all areas of the ABP exam blueprint
- Discounted bundle price for purchasing two online modules and receive printed book at no additional cost
- More value for your money – Complete both modules and earn up to 32 *AMA PRA Category 1 Credits™* and 40 MOC Part 2 points

Great value: Receive the book and online module for one price
- 160 interactive case-based questions make it the ideal tool for certification or recertification prep
- Earn up to 50 *AMA PRA Category Credits™*

For more information or to order, visit endoselfassessment.org
COVER Story

14 Statins: Rap Sheet or Bum Rap?
By Terri D’Arrigo
Cholesterol-lowering drugs are taken by more than 20 million Americans, but the fears of possible side effects have sounded an alarm among patients and doctors. How do you see beyond the hype and the hysteria?

17 Price Gouging
By Kelly Horvath
Baby boomers are seeing an increase in longevity. And so are the chronic ailments that afflict them, most notably diabetes. Diabetes costs will total almost $250 billion annually. Before this staggering economic burden finally topples the healthcare industry, the key to curtailing costs lies in one simple word: Prevention.

24 Gaping Holes Seen in Electronic Record Security
By Eric Seaborg
Electronic health records could be a tempting target for hackers because the software is vulnerable, but workers’ habits can be even worse. It’s time for your practice to adopt a culture of security awareness.

42 Hormone Health Network Fact Sheet: Goiter: Symptoms, Causes & Treatments Your Patients Need to Know

DEPARTMENTS

8 President’s Viewpoint
Introducing Teresa K. Woodruff, PhD

9 Editor’s Page
New editor highlights July issue

10 Trends & Insights
News from the latest research

20 Laboratory Notes
Diamonds may hold the key to extending the life of a sperm

23 Practice Resources
Pediatric Self-Assessment Program: What is causing a toddler’s sudden illness?

26 Research Roundup
Studies in the Society journals

27 InTouch
Society & member news

40 Classifieds
Job opportunities
The Endocrine Society is pleased to welcome its president for 2013–2014, Teresa K. Woodruff, PhD, who took office June 19. Woodruff is a leading expert in reproductive endocrinology and vice chair for research in the Department of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University. She coined the term “oncofertility” to describe her work researching female reproductive health and infertility and translating her findings to the clinical care of women who will lose their fertility due to cancer treatments. She has co-edited three books on the subject, detailing everything from procedural guidelines and best practices to the ethical, religious, economical, and legal implications of preserving fertility in cancer patients.

She also advocates for gender specificity in clinical trials in order to reach a better understanding of the effects that medicine has on women, and she founded the Women’s Health Research Institute at Northwestern University to develop programs to better serve women’s health. She has served on The Endocrine Society Council and has been recognized nationally, receiving numerous awards and honors for her work.

Woodruff succeeds William F. Young Jr. MD, MSc, as the Society continues its rotation of presidents who represent its core constituencies: basic researchers, clinical researchers, and clinical practitioners. “It was a tremendous honor to be selected by my peers to lead this organization for a short period of time,” she says. “As volunteer members, we all contribute to the health of our field, and I look forward to serving with the leadership and committee members.”

Woodruff joined The Endocrine Society 25 years ago, influenced by her mentors at Northwestern University, Kelly Mayo and Neena Schwartz, who also both served as presidents of the Society. “I’m somewhat homozygous for the endocrine science phenotype,” she says.

One of her first experiences as a Society member was in New Orleans in 1988, where she admits she was a little star struck, presenting a paper on the cloning of the subunits for the hormone inhibin and showing how they were regulated during the reproductive cycle of the rodent “in front of a packed room of endocrinology super luminaries — folks that I had read about but never met.”

She says she was inspired by Society members almost immediately, discovering new avenues and concepts in member impact and value. “My first committee was on membership,” she recalls. “Gwen Childs was the chair [of the Membership Committee] and a real activist. I imprinted on her way of thinking outside the box.”

Now that she’s something of a super luminary herself, Woodruff plans to inspire Society members in the coming year, describing her goals of developing a new look for the Society, including a new logo that “refreshes the way we present ourselves to the world,” as well as creating a tagline “that has momentum and expresses our goals and our values.”

But it’s not just about aesthetics; she plans to introduce even more tangible member benefits, including new awards categories that reward members for their achievements, accelerating the careers of the newest society members, and creating a new program called “Leap” that represents the most innovative science and the best scientists in endocrinology. “Reward, Accelerate, Leap,” Woodruff says, “our bold new awards program that increases the visibility of people and ideas.”

Woodruff hopes these fresh approaches translate to new tactics and implementation plans for tackling the “grand global challenges” in endocrinology, including the colliding epidemics of obesity and diabetes, the increasing health risks of endocrine disruptors, the fulcrum between global population expansion and personal reproductive needs, and the support of endocrine science in a low-resource environment.

“We have to be a society about solutions,” she says. “We have to invest in next generation innovators and advocate for them with funding agencies and governments around the globe.”

“We have to be a society about solutions,” she says. “We have to invest in next-generation innovators and advocate for them with funding agencies and governments around the globe.”

—Derek Bagley is associate editor of Endocrine News
Another ENDO has passed and as I’m sure you noticed if you made it to San Francisco, it was a roaring success, with attendance records being broken almost every single day. The sessions were nothing short of amazing in terms of the amount of information that was shared. For me, it was a great opportunity to meet so many of you in person, and I can assure you that I returned to the East Coast with more than my fair share of story ideas and sources for a dozen years’ worth of Endocrine News!

And speaking of timely information, this issue is loaded with stories about topics currently in the forefront of our national consciousness. On page 14, Terri D’Arrigo delves into the controversies surrounding statins, those cholesterol-lowering drugs that are prescribed to over 20 million of us. These drugs are being blamed for a litany of side effects including memory loss and diabetes. Physicians are now determining whether these alleged “wonder drugs” are as wonderful as first thought. Are the possible side effects worth it? In many cases it simply boils down to what’s worse, a heart attack or diabetes? Rest assured, this is an issue that won’t be going away any time soon.

As the baby boomer population lives longer, the incidence of chronic maladies is also on the rise. None is more prevalent than diabetes, with an estimated 22 million people suffering from it in 2012. To no one’s surprise, the financial burden of this disease is almost $250 billion, according to a study by the American Diabetes Association. In “Price Gouging” on page 17, Kelly Horvath comes to the realization that the solution to stop these spiraling costs rests with the physician as well as with the patient. The old adage about “an ounce of prevention” has never been more relevant.

Apparently diamonds aren’t just a girl’s best friend anymore; they’re also a sperm’s. Former Endocrine News associate editor Jacqueline Ruttiman writes about research that shows how diamond-coated petri dishes improve the survival rate for sperm used in IVF procedures, thus increasing the success rates for parents-to-be (page 20). Of course, the addition of diamonds to the mix is only going to increase the spiraling costs. Rest assured, this is an issue that won’t be going away any time soon.

As the baby boomer population lives longer, the incidence of chronic maladies is also on the rise. None is more prevalent than diabetes, with an estimated 22 million people suffering from it in 2012. To no one’s surprise, the financial burden of this disease is almost $250 billion, according to a study by the American Diabetes Association. In “Price Gouging” on page 17, Kelly Horvath comes to the realization that the solution to stop these spiraling costs rests with the physician as well as with the patient. The old adage about “an ounce of prevention” has never been more relevant.

As the baby boomer population lives longer, the incidence of chronic maladies is also on the rise. None is more prevalent than diabetes, with an estimated 22 million people suffering from it in 2012. To no one’s surprise, the financial burden of this disease is almost $250 billion, according to a study by the American Diabetes Association. In “Price Gouging” on page 17, Kelly Horvath comes to the realization that the solution to stop these spiraling costs rests with the physician as well as with the patient. The old adage about “an ounce of prevention” has never been more relevant.

Mark A. Newman
Managing Editor, Endocrine News
PAID DIETERS Lose More Weight

With obesity contributing to “presenteeism,” a lack of productivity while at work due to health problems, employers are looking for ways to combat this costly problem. A new study shows that one way they could save money is by paying their employees to lose weight.

Jeffrey Kullgren, MD, MS, MPH, at the University of Michigan, and his team of researchers divided 105 obese dieters (body mass index 30–40 kg/m^2) into three groups: a control group given links to an online weight-loss network to participate in monthly weigh-ins; a second group who were additionally offered a monthly $100 incentive to meet their individual weight-loss goal; and a third, who were subdivided into groups of five to split $500 among only those group members who met their goals (thus building in the possibility of a bigger payout if not all five met goals). In their paper, to be published soon in the *Annals of Internal Medicine*, the researchers report that the third group lost on average 4.4 kg more weight than the non-incentivized control group and 3.2 kg more than the individually incentivized group after 24 weeks of dieting. However, 12 weeks post-incentive, the individual-incentive group had kept off an average of 2.7 kg more weight than the group-incentive group. The researchers conclude that the prospect of a bigger cash reward among the group-incentive participants was the strongest motivator to lose weight. Maintaining that loss over the long term might also be more successful if the incentive plan is likewise continued.

— Kelly Horvath

Group Clinics Improve Outcomes, KEEP COSTS DOWN

With chronic diseases such as diabetes requiring constant management and never-ending medical bills, group medical clinics (GMCs) have been shown to be effective at managing diabetes. Are they also cost effective? George L. Jackson, PhD, MHA, at the Durham Center for Health Services Research in Primary Care in North Carolina, and his team of scientists recently studied 239 people with poorly controlled diabetes receiving either usual care or attending GMCs every two months for one year. GMC attendance included education and structured interactions among the up to eight group members, and the care team comprised registered nurses, certified diabetes educators, pharmacists, and general internists. Diabetes in the GMC group was more successfully managed, with lower systolic blood pressure and cholesterol levels. In their follow-up paper, to be published soon in the *Journal of the American Medical Association: Internal Medicine*, the researchers report that the diabetic patient who successfully managed, with lower systolic blood pressure and cholesterol levels. In their follow-up paper, to be published soon in the *Journal of the American Medical Association: Internal Medicine*, the researchers report that the third group lost on average 4.4 kg more weight than the non-incentivized control group and 3.2 kg more than the individually incentivized group after 24 weeks of dieting. However, 12 weeks post-incentive, the individual-incentive group had kept off an average of 2.7 kg more weight than the group-incentive group. The researchers conclude that the prospect of a bigger cash reward among the group-incentive participants was the strongest motivator to lose weight. Maintaining that loss over the long term might also be more successful if the incentive plan is likewise continued.

— Kelly Horvath

**TRENDS & INSIGHTS**

**STATINS OFTEN PRESCRIBED** with No Likely Benefit

Statins cost the healthcare system more than $20 billion a year and may be overprescribed to patients who are not at high risk for coronary heart disease (CHD).

Michael E. Johansen, MD, at the University of Michigan, Ann Arbor, and his team of scientists anonymously surveyed 202 family and internal medicine and cardiology physicians on their treatment choices in six clinical vignettes, each concerning a hypothetical patient ranging from age 40 to 75 years with various baseline risk factors for hyperlipidemia (e.g., high “bad” cholesterol or blood pressure level, diabetes, smoking), but none with existing CHD. In their paper, to be published soon in the *Journal of the American Medical Association: Internal Medicine*, the researchers report that most physicians (70%) would have prescribed a statin to even the patients with very low risk for developing CHD anytime soon yet fewer than half would have prescribed a statin for the diabetic patient who may have benefited most. The researchers conclude that physicians prescribe statins almost reflexively, focusing solely on cholesterol levels and without adequately weighing the risk–benefit ratio. Lifestyle modification (e.g., quitting smoking, eating well, and exercising) is most effective in many patients with high cholesterol but no other CHD risk factors, they add.

— Kelly Horvath
Couples who take longer to conceive may be at higher risk of having children born with mild neurological problems, according to new research. Babies born through in vitro fertilization (IVF) have an increased risk of being born prematurely or having a low birth weight, possibly leading to a developmental disorder. But what has been previously linked to the IVF treatments, the developmental problems actually may be connected to what initially caused the couples’ infertility.

In an article appearing in *Archives of Disease in Childhood: Fetal & Neonatal* edition, researchers from The Netherlands examined 209 two-year-old children who were born to subfertile parents. The couples had taken between 1.6 and 13.2 years to conceive. More than half of the couples had undergone IVF.

The study, led by Jorien Seggers of the University of Groningen, assessed the children’s neurological development by testing their movement, muscle tone, reflexes, gross and fine motor function, and hand-eye coordination. Results showed that minor neurological dysfunction (MND) was present in 16 children (7.7%). In the children with MND, couples took an average of 4.1 years to become pregnant compared with an average of 2.8 years in couples with children born without MND. Taking longer to get pregnant was linked with a 30% higher risk of having a baby with MND.

— Glenda Fauntleroy

---

**GUT MICROBIOTA Important for Healthy Metabolism**

For years, scientists have wondered why roux-en-Y gastric bypass (RYGB), the most widely done form of gastric bypass surgery, results not only in rapid weight loss but also in an even faster return to normal glucose metabolism, suggesting that the latter effect is not due strictly to decreased caloric intake or absorption. A new study tests whether the changes RYGB causes in the makeup of gut microbes accounts for the additional effects.

Doctors Lee Kaplan, MD, PhD, at the Harvard Medical School, Massachusetts, and Peter Turnbaugh, PhD, at Harvard’s Center for Systems Biology, and their team of researchers divided 23 mice into an RYGB group, a sham surgery group, and a sham surgery coupled with caloric restriction group, analyzing their fecal samples before surgery and then weekly for 12 weeks. In their paper, published in *Science Translational Medicine*, the researchers report increases in proteobacteria and verrucoinbacteria and a decrease in firmicutes in the RYGB and the dieting groups, with more dramatic and rapid changes among the RYGB group. When proteobacteria and verrucoinbacteria were transferred to mice guts in the sham surgery group, rapid weight loss resulted.

The researchers conclude that the changes in gut bacteria account for the metabolic benefits seen after RYGB, possibly by increasing levels of short-chain fatty acids, which speed up metabolism. Manipulating the gut microbiota without surgery could be a potential new therapy to address obesity in humans, they add.

— Kelly Horvath

---

**FISH OIL LENGTHENS LIFESPAN Among Older Adults**

Eating fish and seafood, foods that are unique in containing long-chain polyunsaturated omega-3 fatty acids, can improve cardiovascular and brain health. A new study examines for the first time whether these benefits might help us live longer.

Darius Mozafarian, MD, DrPH, at the Harvard School of Public Health, Massachusetts, and his team of researchers analyzed blood level data of three types of omega-3 fatty acid from 2,692 healthy U.S. adults ages 69–79 years who participated in the National Heart, Lung, and Blood Institute’s 1992–2008 Cardiovascular Health Study. In their paper, to be published soon in the *Annals of Internal Medicine*, the researchers report that docosahexaenoic acid lowered risk of coronary heart disease (CHD) death by 40%, eicosapentae-
Adolescent Bariatric Surgeries Decline While OBESITY RATES SOAR

With childhood obesity at an all-time high — one in three kids is overweight or obese — effective strategies to combat this epidemic and its comorbid diseases are vital. Is adolescent bariatric surgery one such strategy?

Deirdre C. Kelleher, MD, at the Children’s National Medical Center, Washington, D.C., and her team of scientists retrospectively analyzed data from the Healthcare Cost and Utilization Project Kids’ Inpatient Database for the decade 2000–2009 to determine rate of bariatric surgery in adolescents (ages 10–19 years) and characterize related trends. In their paper, to be published soon in the Journal of the American Medical Association: Pediatrics, the researchers report that procedure rates increased considerably during the first three years (from 328 to 987) but subsequently plateaued. Type of procedure, length of hospital stay, and complication rates also changed: Minimally invasive (i.e., laparoscopic) procedures are now more likely to be done than open procedures, reducing both hospital stay and complications.

The researchers also found that males and younger adolescents are less likely to undergo the surgery than females age 17 years and older with private insurance. Those with low socioeconomic status and on Medicaid are also in the minority. Their data underscore the disparity between obesity rates and use of low-risk, minimally invasive bariatric surgery that could improve or even save many lives.

— Kelly Horvath

Fast FACTS About Statins

1 in 4 Americans takes cholesterol-lowering statins.

6 out of 100,000 patients on statins suffered from rhabdomyolysis, which causes permanent muscle death.

Approximately 130 people need to take statins for a year to prevent just one unwanted health outcome.

500 people have to take statins to prevent a single death.

Sources: WebMD, CDC, Scientific American, Annals of Internal Medicine
Biotechnology vs Cardiovascular Disease. The fight is on.

For the scientists at Amgen, that fight is personal. With millions suffering a cardiac event each year, we are never far from being touched by cardiovascular disease ourselves—be it a family member’s health issue, a friend’s, or our own. As we use the power of biotechnology to pioneer new therapeutics, we are determined to alter the course of this global epidemic. Because behind the statistics is one vital thing: the lives of people we know.
STATINS:
Are the side effects from cholesterol-lowering drugs worth the risk?

By Terri D’Arrigo

When the Food and Drug Administration (FDA) announced labeling changes to cholesterol-lowering statins in February of last year, the media were quick to sound the alarm. Headlines proclaimed that statins raise the risk of diabetes and cause memory loss. Debate arose about side effects and whether statins, taken by more than 20 million Americans, were overprescribed. Suddenly, an entire class of wonder drugs wasn’t so wonderful anymore.

But more recent evidence suggests that there’s more to the statin story. Analyses of three major trials — including one the FDA cited in its warnings about diabetes — revealed that increased rates of diabetes in statin users depended on whether they already had risks for the disease before starting the drugs. Another study demonstrated that not only were statins well-tolerated in patients who had previously stopped taking them because of side effects, but that reports of memory problems in particular were rare. Yet this news did not garner as much attention in the mainstream consumer media.

What gives?
“A lot of media attention focuses on things that create sensation,” said Anne Carol Goldberg, MD, FACP, associate professor of medicine at the Washington University School of Medicine in St. Louis. “But what physicians have to do is educate patients on the reality, which is that these drugs
save lives, particularly among people at high risk for cardiovascular disease.”

Goldberg said she encounters resistance to statins among her patients, in part because of what they hear anecdotally or in the news. “People are afraid of them and think they cause bad effects. I will show patients figures from the Cholesterol Treatment Trialists Collaboration [CTT] and explain what we actually see in terms of benefits,” she said.

The CTT is a group of physicians and researchers in the United Kingdom who conduct periodic meta-analyses of large randomized trials of lipid-lowering treatments. In the November 13, 2010, issue of *The Lancet*, the CTT published a meta-analysis, of 26 randomized trials involving more than 169,000 participants wherein they found that reducing LDL cholesterol by 38 to 77 mg/dl via statins reduces the risk of vascular events such as heart attack, coronary revascularization, and stroke by 40% to 50%. More recently, in the August 11, 2012, issue of *The Lancet*, the CTT published a meta-analysis of 27 randomized trials involving more than 174,000 patients, which revealed that even low-risk patients who would not normally be considered for statin therapy derive as much risk reduction for vascular events from statins as high-risk patients do.

**Diabetes Risk**

The labeling for statins now includes a warning that there have been reports of increased blood glucose and A1c measurements in people who take the drugs. Among its reasons for the warning, the FDA cited findings from the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, which noted a 27% increase in investigator-reported diabetes in patients who took rosuvastatin compared to those who took placebo.

In light of the warnings, JUPITER researchers further analyzed data from the trial’s 17,603 participants to weigh the benefits of statins against the risk of diabetes. As noted in the August 11, 2012, issue of *The Lancet*, they found a 28% increase in diabetes among statin users who already had one or more major risk factor for the disease. The team also learned that 134 vascular events or deaths were avoided for every 54 new diagnoses of diabetes, leading them to conclude that the cardiovascular benefits of statin therapy exceed the risk of developing diabetes.

A more recent analysis of data from two other studies with a combined 15,056 participants, Treating to New Targets (TNT) and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering (IDEAL), yielded similar results. In this analysis, published in the January 15, 2013, issue of the *Journal of the American College of Cardiology*, researchers compared 80 mg/day of atorvastatin with 10 mg/day atorvastatin or 20–40 mg/day of simvastatin to assess vascular benefits and diabetes risk. They saw a 24% increase in high-dose participants who already had two to four diabetes risk factors, and no increased diabetes in high-dose participants with no or only one risk factor for diabetes, compared to low-dose participants. Yet compared to low doses, the higher dose reduced the number of cardiovascular events in patients regardless of how many diabetes risk factors they had.

It boils down to severity, said David Waters, MD, professor emeritus at the University of California — San Francisco and lead investigator in the TNT/IDEAL analysis. “If you think about diabetes and cardiovascular disease, the two really aren’t equivalent. Developing diabetes is bad, but having a heart attack or stroke and dying is worse.”

Although diabetes itself raises the risk of cardiovascular disease, populations at risk for both tend to overlap, Waters said. “These are people with high blood pressure, higher than normal fasting glucose, high BMI and [bad] family histories. Either way, they’re going to benefit from statin therapy.”

**AT-A-GLANCE:**

- In 2012 the FDA announced labeling changes to cholesterol-lowering statins to include warnings about diabetes risk and memory loss.
- Analyses of the JUPITER, TNT, and IDEAL trials revealed that increased rates of diabetes in statin users depended on whether they already had risks for the disease before starting the drugs.
- A study published this year in the *Annals of Internal Medicine* suggests that memory loss from statins is rare and that statins are well-tolerated.
Like Goldberg, Waters has patients who hesitate to take statins. He addresses their concerns by emphasizing risk minimization. “Say a patient has a high BMI. They’ll say they’re afraid taking a statin will give them diabetes. But if they lose weight, they can cut their risk of developing diabetes right there.”

Waters has a bone to pick with what he sees as a bias against statins. “A lot of other drugs out there increase the risk of diabetes.”

The Question of Side Effects

Statin labeling now includes a warning that cognitive effects such as memory loss and confusion have been reported in people who take the drugs. The FDA based its warning on reports received through its Adverse Event Reporting System (AERS), where clinicians and patients voluntarily report what they feel to be side effects of the drugs, and noted that the reports generally described people in their 50s or older who experienced noticeable, if poorly defined, memory loss or impairment that disappeared when they stopped taking statins.

However, a study by researchers in the April 2, 2013, *Annals of Internal Medicine* suggests that memory loss from statin use may actually be rather rare. In the study, which was designed to ascertain the reasons for statin discontinuation and the role of statin-related events in routine care settings over eight years, memory loss was reported in only 0.06% of participants, or less than 1 in 1,000. Among the 107,835 participants in the study, 18,778 patients, or 17.4%, had documented statin-related side effects. Muscle pain was the most common side effect, experienced by 4.71% of patients in the study overall. Of those who had side effects, 11,124 stopped taking statins. Then 6,579 began taking statins again. The drugs were well-tolerated the second time around for these patients, as 92.2% of them were still taking statins a year after resuming therapy.

Alexander Turchin, MD, MS, associate physician at Brigham and Women’s Hospital, assistant professor of medicine at Harvard Medical School in Boston, and the senior author of the study, acknowledges that there is a discrepancy between clinical trials’ reported rates of adverse reactions such as muscle pain and what physicians are observing anecdotally in routine care. “If you talk to doctors on the front lines and their patients, you’re constantly hearing about these reactions,” he said. “But in the clinical trials, their incidence is similar between statin and placebo arms.”

This could be for a number of reasons, he said. “Clinical trial participants who pass eligibility criteria tend to be healthier overall. On the other hand many of the symptoms that are reported as attributable to statins are not very specific, such as muscle pain. Sometimes the symptoms are specific to an individual statin or a higher dose. Other times the symptoms might not be from statins at all, but another underlying condition. We think our data implies a range of explanations.”

Turchin added that the older age of many statin users can make it difficult to root out whether their memory loss is actually from statins. “Older patients are at higher risk for vascular dementia from multiple strokes and for the onset of Alzheimer’s disease. This can paint a mixed picture both clinically and pathologically. It’s not an easy diagnosis to make.”

William James Howard, MD, MACP, director of MedStar Washington Hospital Center’s Lipid Clinic and Lipid Consultation services in Washington, D.C., cautioned against awareness of potential side effects becoming a self-fulfilling prophecy. “One of the problems is that we have created a monster,” he said. “Most people get some muscle or joint pain as they get older, and they tend to ignore it.

“It’s not a simple pill that will take away all your risk for vascular dementia from multiple strokes and for the onset of Alzheimer’s disease. This can paint a mixed picture both clinically and pathologically. It’s not an easy diagnosis to make.”

But if it’s in the back of your mind because you’ve been warned about it in commercials and the news, if you have muscle pain, you’ll think, ‘Oh, it’s the statin,’ when really it might be because you’re 60 and 60-year-olds tend to have a few aches and pains.”

Howard counters the power of suggestion by having patients keep a diary for a few days before starting statin therapy. They record whether, where, and when they have pain or other symptoms so that both physician and patients know what kinds of issues already existed before starting the statin. The sheer number of people who take statins makes compiling statistics tricky, Howard said. “If you have millions of people on any drug, you will have associations with anything imaginable, whether it’s memory loss, insomnia, peripheral neuropathy, and so on. But that doesn’t mean there’s a cause-and-effect relationship,” he said. “As we move forward with the research, we really need to separate out causation versus association.”

And so the statin story will continue to unfold.

—D’Arrigo is a health and science writer based in Holbrook, N.Y., and a regular contributor to Endocrine News
Aging baby boom population coupled with increasing human longevity has combined to dramatically increase incidence of chronic disease, particularly diabetes. Increasing by 5 million in just five years, 22.3 million people were living with diabetes in 2012.

The economic burden of diabetes grows even faster than its incidence. Diabetes costs, both direct and indirect, will total around $245 billion for 2012, according to the April 2013 Scientific Statement by the American Diabetes Association (ADA), “Economic Costs of Diabetes in the U.S. in 2012.” This staggering figure reflects a five-year increase in diabetes costs greater than the overall cost of medical care as a whole (which holds true even after adjusting for inflation). The ADA last undertook an economic burden study in 2007; at that time, diabetes costs were $174 billion. (Other costs not included in the ADA figure include undiagnosed diabetes, which is estimated to cost another $18 billion; prediabetes, another $25 billion; and unknown hidden costs, such as those incurred by nonpaid caregivers or by family members living with diabetes patients.)

**Direct and Indirect Costs**

Of the $245 billion, direct costs command the larger share at $176 billion, and indirect costs come in around $69 billion. Direct costs include emergency room care, hospital inpatient days, nursing/residential facility use, ambulance services, ambulatory visits, hospice care, podiatry, prescription medications, diabetic supplies, and other equipment and supplies, whereas indirect costs are associated with productivity loss from a combination of absenteeism (workdays missed due to health conditions), presenteeism (reduced work productivity while at work due to health conditions), reduced workforce participation among those with chronic disability, and the productivity lost from premature mortality. Direct and indirect costs break down by age group as well, with most (59%) direct costs attributable to patients ages 65 years and older, whereas 88% of indirect costs derive from those younger than age 65 years.

Not surprisingly, the disease costs substantially more (study findings show from two to eight times higher) when it is poorly controlled and/or associated with complications. Diabetes-related conditions accounting for most of the overall direct costs include heart and renal failure; heart disease, such as conduction disorders, cardiac dysrhythmias, hypertension, myocardial infarction, and chronic ischemic heart disease; cataracts; cellulitis; urinary tract infections; and poor general health.

These conditions combine to increase annual medical expenditures for people with diabetes by 2.3 times over those without the disease. In fact, according to the ADA, “More than one in 10 healthcare dollars in the U.S. are spent directly on diabetes and its complications, and more than one in five healthcare dollars in the U.S. goes to the care of people with diagnosed diabetes.” Notably, hospital inpatient care is the largest piece of this spending, having risen to 48% (from $58 billion in 2007 to $76 billion in 2012), despite overall hospital inpatient care costs having decreased: of total direct medical costs, inpatient care dropped from 50% to 43% in the same five-year period.

How and why costs have skyrocketed by 41% in five years to $245 billion seems to have less to do with specific economic factors (i.e., treatment costs rising) than with sheer disease predominance, according to the ADA. Diabetes prevalence reflects changing demographics (i.e., older adults show a greater prevalence, and the numbers of older adults are increasing both as baby boomers age and people live longer in general); increases in risk factors, especially obesity; decreasing mortality (i.e., people are living longer with disease due to improved treatments), and better disease detection. Some say that if incidence continues to burgeon, one in three people will be diagnosed with diabetes by 2050. Matt Petersen, managing director, Medical Information and Professional Engagement of the ADA, says, “I believe the key observation to make is that the increased cost from 2007 to 2012 is primarily a result of increased prevalence of diagnosed diabetes. One might think that the availability of new and often expensive medications would have contributed to that increased cost, but in fact the...
proportion of the cost attributable to anti-diabetic agents remained flat during that time.”

Despite the availability of several new diabetes medications and despite double the use of such agents, overall pharmacy costs stayed more or less constant over a 10-year period at 12% of diabetes medical spending in 2012. Interestingly, prescriptions to treat diabetes complications cost significantly more than did prescriptions to treat diabetes — at 18% and 12%, respectively.

Reducing Costs

Everyone agrees that this steadily increasing economic burden is overwhelming the U.S. healthcare system. Medicare currently shoulders the costs incurred by 14 million people living with diabetes — almost half of the diagnosed population. Among Medicare, Medicaid, and military programs, in fact, the U.S. federal government pays for 62% of diabetes-related costs. U.S. federal government 2014 budget proposals to reduce this outlay include shifting more costs to wealthier Medicare recipients and cutting about $350 billion from providers and recipients. Opponents fear that such sweeping changes would limit care access for the biggest and most needy populations — low-income, older, and disabled diabetes patients — as well as cause an overall regression in public health. Other measures, such as the program hosted by the Centers for Medicare and Medicaid that allows patients to mail order their medications and equipment from suppliers who competitively bid to participate (commonly known by the acronym DMEPOS), saved only $202 million in 2011.

The dilemma presented by these current and proposed measures (i.e., effectively reducing care access on the one hand and not saving enough money on the other) leaves many asking, how, then, do we pay this ever-increasing bill? In the healthcare sector, however, many say we are approaching the issue from the wrong angle. We should not be looking at how to pay the bill so much as how to prevent the cost from being incurred.

“"If the primary driver of the increased costs is increased prevalence, it’s a compelling argument that we should be looking at primary prevention of type 2 diabetes as the most important strategy for containing the costs,” says Petersen.

“And prevention of course would not only reduce economic costs, but would also bring the quality-of-life benefits that would come from preventing diabetes in the first place.”

Hospital inpatient care is the largest piece of the cost pie (one day is estimated to cost $5,000), but preventing diabetes (or even effectively controlling it) would directly mitigate that expenditure by negating the trip to the hospital.

Thus, the answer to at least part of this problem is self-evident, say physicians and researchers, and is also long backed up by findings from the 2002 Diabetes Prevention Program (DPP). If 95%—98% of diabetes is type 2, and if the risk of developing type 2 diabetes is dramatically increased by obesity, then we need lifestyle interventions targeting obesity to prevent diabetes from developing and thereby stanch the increase in the diabetes base population, which some say is growing by 5,000 people a day.

“We feel prevention is paramount for reducing the future cost of the condition,” says Kelly L. Close, president of Close Concerns, a diabetes awareness organization, and editor-in-chief of diaTribe, an online diabetes news journal. For the other part of the problem, that is, those already diagnosed with diabetes, the answer is optimizing care, she says, adding, “We would like to move away from the ‘treat to failure’ model that so many patients get caught in and move toward new therapies.”

“We would like to move away from the ‘treat to failure’ model that so many patients get caught in and move toward new therapies.” — Kelly Close, president, Close Concerns; editor, diaTribe

The dilemma presented by these current and proposed measures (i.e., effectively reducing care access on the one hand and not saving enough money on the other) leaves many asking, how, then, do we pay this ever-increasing bill? In the healthcare sector, however, many say we are approaching the issue from the wrong angle. We should not be looking at how to pay the bill so much as how to prevent the cost from being incurred.

“If the primary driver of the increased costs is increased prevalence, it’s a compelling argument that we should be looking at primary prevention of type 2 diabetes as the most important strategy for containing the costs,” says Petersen.

“And prevention of course would not only reduce economic costs, but would also bring the quality-of-life benefits that would come from preventing diabetes in the first place.”

Hospital inpatient care is the largest piece of the cost pie (one day is estimated to cost $5,000), but preventing diabetes (or even effectively controlling it) would directly mitigate that expenditure by negating the trip to the hospital.

Thus, the answer to at least part of this problem is self-evident, say physicians and researchers, and is also long backed up by findings from the 2002 Diabetes Prevention Program (DPP). If 95%—98% of diabetes is type 2, and if the risk of developing type 2 diabetes is dramatically increased by obesity, then we need lifestyle interventions targeting obesity to prevent diabetes from developing and thereby stanch the increase in the diabetes base population, which some say is growing by 5,000 people a day.

“We feel prevention is paramount for reducing the future cost of the condition,” says Kelly L. Close, president of Close Concerns, a diabetes awareness organization, and editor-in-chief of diaTribe, an online diabetes news journal. For the other part of the problem, that is, those already diagnosed with diabetes, the answer is optimizing care, she says, adding, “We would like to move away from the ‘treat to failure’ model that so many patients get caught in and move toward new therapies.”

The dilemma presented by these current and proposed measures (i.e., effectively reducing care access on the one hand and not saving enough money on the other) leaves many asking, how, then, do we pay this ever-increasing bill? In the healthcare sector, however, many say we are approaching the issue from the wrong angle. We should not be looking at how to pay the bill so much as how to prevent the cost from being incurred.

“If the primary driver of the increased costs is increased prevalence, it’s a compelling argument that we should be looking at primary prevention of type 2 diabetes as the most important strategy for containing the costs,” says Petersen.

“And prevention of course would not only reduce economic costs, but would also bring the quality-of-life benefits that would come from preventing diabetes in the first place.”

Hospital inpatient care is the largest piece of the cost pie (one day is estimated to cost $5,000), but preventing diabetes (or even effectively controlling it) would directly mitigate that expenditure by negating the trip to the hospital.

Thus, the answer to at least part of this problem is self-evident, say physicians and researchers, and is also long backed up by findings from the 2002 Diabetes Prevention Program (DPP). If 95%—98% of diabetes is type 2, and if the risk of developing type 2 diabetes is dramatically increased by obesity, then we need lifestyle interventions targeting obesity to prevent diabetes from developing and thereby stanch the increase in the diabetes base population, which some say is growing by 5,000 people a day.

“We feel prevention is paramount for reducing the future cost of the condition,” says Kelly L. Close, president of Close Concerns, a diabetes awareness organization, and editor-in-chief of diaTribe, an online diabetes news journal. For the other part of the problem, that is, those already diagnosed with diabetes, the answer is optimizing care, she says, adding, “We would like to move away from the ‘treat to failure’ model that so many patients get caught in and move toward new therapies.”

The dilemma presented by these current and proposed measures (i.e., effectively reducing care access on the one hand and not saving enough money on the other) leaves many asking, how, then, do we pay this ever-increasing bill? In the healthcare sector, however, many say we are approaching the issue from the wrong angle. We should not be looking at how to pay the bill so much as how to prevent the cost from being incurred.

“If the primary driver of the increased costs is increased prevalence, it’s a compelling argument that we should be looking at primary prevention of type 2 diabetes as the most important strategy for containing the costs,” says Petersen.

“And prevention of course would not only reduce economic costs, but would also bring the quality-of-life benefits that would come from preventing diabetes in the first place.”

Hospital inpatient care is the largest piece of the cost pie (one day is estimated to cost $5,000), but preventing diabetes (or even effectively controlling it) would directly mitigate that expenditure by negating the trip to the hospital.

Thus, the answer to at least part of this problem is self-evident, say physicians and researchers, and is also long backed up by findings from the 2002 Diabetes Prevention Program (DPP). If 95%—98% of diabetes is type 2, and if the risk of developing type 2 diabetes is dramatically increased by obesity, then we need lifestyle interventions targeting obesity to prevent diabetes from developing and thereby stanch the increase in the diabetes base population, which some say is growing by 5,000 people a day.

“We feel prevention is paramount for reducing the future cost of the condition,” says Kelly L. Close, president of Close Concerns, a diabetes awareness organization, and editor-in-chief of diaTribe, an online diabetes news journal. For the other part of the problem, that is, those already diagnosed with diabetes, the answer is optimizing care, she says, adding, “We would like to move away from the ‘treat to failure’ model that so many patients get caught in and move toward new therapies.”

The Endocrine Society is fully in agreement that prevention is paramount and urges the federal government to likewise recognize this necessity. The Society’s director of government and public affairs Stephanie Kutler says, “The Society has been working with members of Congress to secure full funding for the [DPP], and the new [ADA] data have helped to illustrate the urgency of our message. These costs will continue to grow unless we do something to prevent more people from developing diabetes, and the proven way to do that is through primary prevention programs like the DPP. But Congress and the Administration must make this a priority and fully fund the program.”

Investing in new drugs and technology as well as in public health programs on diabetes prevention seems to be the consensus among the healthcare sector. “More research into new prevention programs and treatments and cures” should also be a priority, adds Kutler. Perhaps legislators will realize that a twist on the old quote might apply here: “You must spend money to save money.”

—Horvath is a freelance writer in Baltimore, and a regular contributor to Endocrine News
Bring your biomarkers to life. The best, most relevant assays for metabolism research.

For a complete picture of metabolic disease you need to analyze data for multiple proteins from multiple systems. To help you discover the biology in your data, we’ve built the largest portfolio of assays for both circulating and intracellular biomarkers and a complete spectrum of trusted Luminex® instrumentation.

Our quality manufacturing of MILLIPLEX® MAP assay panels and ELISAs gives you the same accuracy and precision in every lot, backed by the same, unwavering technical support.

Bring your research to life: emdmillipore.com/MILLIPLEX

Multiplex analysis of plasma samples using MILLIPLEX® MAP Cardiovascular Disease (CVD) Panels shows significantly elevated biomarkers in CVD patient samples.

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

EMD Millipore and the M logo are trademarks and MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany. Trademarks belonging to third parties are the properties of their respective owners. © 2013 EMD Millipore Corporation, Billerica, MA USA. All rights reserved.
LABORATORY NOTES

DIAMONDS in the Rough

By Jacqueline Ruttimann Oberst


“Our finding is likely to change the world of the petri dish,” explains Andrei Sommer, PhD, a materials scientist at Ulm University in Germany and the study’s lead author.

The average IVF cycle in the United States costs $12,400, according to the American Society of Reproductive Medicine. Because its success rate remains rather low, at about 30%, couples often undergo multiple treatment rounds before they successfully conceive. “Poor sperm performance” is a common problem, which typically requires actual injection of sperm into an egg. Yet for decades a part of the solution was right in front of the reproductive endocrinologists’ eyes: the petri dish.

The majority of IVF clinics—about 99.9%—use disposable petri dishes made from polystyrene plastic. When cell medium is applied to these dishes, the surface softens, as verified by a material harness-measuring device called a nanoindenter. The liquefied surface facilitates the formation of reactive oxygen species (ROS) that is toxic to cells, including sperm, oocytes, and embryos.

Searching for ways to get around this problem, Sommer remembered the title of an American Chemical Society press release on his previous work titled, “Diamonds may have been life’s best friend on primordial Earth,” which suggested that the surface of natural diamonds might have provided the right conditions for life-creating chemical reactions. For his research, the title served as a “guiding light sentence” and stimulated the inclusion of nanodiamond-coated petri dishes.

Sommer’s team applied fresh sperm samples, at about 4.1 million/mL — lower than the typical male sperm concentration of 20–200 million/mL — onto four different types of petri dishes: polystyrene, quartz glass, sandblasted quartz glass coated with nanodiamonds, and quartz glass coated with nanodiamonds. After 42 hours at 37 degrees Celsius, about 20% more sperm survived in the pricey petri dishes, specifically the nanodiamond-coated plain and sandblasted quartz dishes, than the bargain polystyrene ones; the plain quartz containers without the diamond dusting yielded about 10% better viability than the polystyrene dishes.

The 42-hour time point could be important because, in IVF, after about 40 hours, the eggs are examined to see if they have become fertilized by the sperm and are forming embryos. The embryos are then placed in the woman’s uterus, thus bypassing the fallopian tubes, and hopefully ensuring pregnancy.

“During conventional IVF, sperm cells and oocytes both contact the bottom of the petri dish before the zygote is formed. These hours, and subsequent days prior to the transfer of the embryo into the recipient, are critical,” said Sommer, who added that sperm, while sensitive to ROS, are more robust to them than oocytes and embryos.

Bradley Anawalt, MD, chief of medicine at the University of Washington Medical Center and specialist in male reproductive physiology, who was not involved in the study, described the work as “a relatively simple and straightforward study that asks a simple question no one has asked before.”

He added that this research backs up prior findings that infertile men are exposed to ROS in their testicles and includes speculation that antioxidant therapies might.
help these men. Given that banked sperm are often frozen in polystyrene containers, Anawalt posits that it is possible these containers could also affect the long-term viability of these frozen sperm.

Richard Rawlins, PhD, IVF laboratory director at Rush-Copley Center for Reproductive Health in Aurora, IL, mentioned that ROS scavengers are typically added to culture media to soak up any ROS in the dishes, yet perhaps these chemicals are not enough. He also called the study “a novel application of engineering helping out biology.”

Sommers’s group plans on testing the plates to see if it has any effect on sperm morphology and motility. They also want to ensure that the diamond coatings are biologically and chemically inert and do not release other toxic chemicals of their own.

The diamond-coated petri dishes are not only sperm and egg’s best friend. They could also aid in culturing stem cells and cancer cells, suggested Sommer, whose lab previously reported greater growth success of P19 mouse embryonic carcinoma cells on the diamond-dusted quartz petri dishes’ substrates.

Although these dishes could theoretically be reused through sterilization techniques such as autoclaving, Sommer correctly points out that “neither the IVF community nor the patients will accept making babies in ‘used’ petri dishes.”

If Sommer’s future research continues to indicate that these plates show promise, companies could start manufacturing these dishes in the next couple of years. And IVF clinics that purchase these dishes would somehow transfer the costs to the patients.

—Ruttimann Oberst, PhD, is a freelance writer in Bethesda, MD and a regular contributor to Endocrine News
Finding new ways to reimburse physicians is a critical next step in reforming America’s healthcare system. Since 2002, physicians have faced potentially devastating payment cuts that have resulted from the flawed payment formula known as the sustainable growth rate (SGR). In 1997, the SGR was mandated by Congress in an attempt to stabilize federal spending and to balance the budget. Each year, target expenditures are established that take into account things like changes to physician service fees and the number of Medicare beneficiaries. If actual expenditures exceed that target, cuts to physician payments the subsequent year must take place to offset the difference.

While Congress typically passes short-term legislative patches to avoid these cuts, this approach to Medicare reimbursement is untenable. This year, physicians can expect to receive a 25% cut in Medicare payments if Congress fails to act. And in order to provide a permanent solution, Congress must find $139 billion.

Because of the high price tag and the general divisiveness in Congress, an alternative approach to reimbursing physicians has not been given serious thought — until recently. Earlier this year, the House committees on Energy & Commerce and Ways & Means released a framework for reforming the Medicare payment system. Much like the trend toward patient-centered care, paying America’s physicians may also be moving toward an individualized approach.

The current congressional proposals promise to give physicians a variety of reimbursement options, rather than taking a one-size-fits-all approach to replacing the SGR. Enabling physicians to choose how they get paid is a fresh take on a system that has long been shackled by formulaic considerations rather than improving the quality of patient care.

So how would this proposal work? First Congress must decide the payment models from which physicians can select. Once these options have been decided, physicians would receive stable payments for several years to give them time to decide which option would work best for their practice. Physicians can continue to be paid under the fee-for-service (FFS) system or they can choose to participate in an alternative payment model that utilizes team-based care to streamline healthcare delivery. The FFS system will also see some changes during this time to integrate quality and performance measures so that future payment updates can take these considerations into account.

Throughout this process, the committees have engaged key stakeholders, like The Endocrine Society, to ensure the alternative payment models that are selected can benefit all specialties. The Society has long advocated for payment reform to better account for the undervaluation of the evaluation and management services that endocrinologists most often provide. The Society has also been supportive of both the SGR repeal and for physicians to be able to select a reimbursement option that is most suitable for their practice.

In comments to the committees regarding this framework, the Society has stressed the importance of working with physician organizations to ensure that there are relevant quality measures for all physicians. The Society also believes that providing flexibility during the selection process of an alternative payment model is a critical step in incentivizing physicians to try out new mechanisms for reimbursement. Comments on implementation, EHR adoption, clinical improvement activities, alternative payment models, and resource utilization were also included in the comment letter, which can be found at www.endocrine.org/advocacy/legislative/letters.
A two-year-old boy is admitted to the hospital for spitting up and poor feeding. He was reportedly healthy until the week of this hospital admission, although his slow growth and lack of weight gain have been a consistent problem for which no definite diagnosis has been given. He was born after a full-term pregnancy to a 24-year-old primigravida woman. Gestation was complicated by early oligohydramnios and relatively poor weight gain, but the birth weight was 3,770 g (68th percentile) and birth length was 50.8 cm (62nd percentile). Although vaginal delivery was attempted, the use of forceps was unsuccessful and cesarean delivery was necessary after a difficult and prolonged labor. There were no other complications, and two days after delivery, the newborn was discharged with his mother.

There is no family history of disease, the child is not taking any medications, and he has not been exposed to any unknown substances. On physical examination, weight is below the fifth percentile and height is at the 10th percentile. He has no dysmorphic features, but he is dehydrated, pale, and lethargic. He has no trauma or rashes. He has normal male genitalia with bilaterally descended testes. An X-ray of the abdomen shows calcifications that are thought to represent kidney stones. Abdominal CT is shown.

Laboratory test results:

- Sodium = 114 mEq/L (136-142 mEq/L)
- Potassium = 7.2 mEq/L (3.5-5.0 mEq/L)
- ACTH = 2,500 pg/mL (10-60 pg/mL)
- Cortisol = 1.2 μg/dL (AM serum cortisol, 10-20 μg/dL)
- 17-Hydroxyprogesterone = 35 ng/dL (AM 17-hydroxyprogesterone 60-300 ng/dL)
- Plasma renin activity = 86 ng/mL per h (0.6-4.3 ng/mL per h)

**QUESTION**

Which one of the following diagnoses is most consistent with the biochemical profile and CT image of this patient?

A. Allgrove syndrome  
B. Familial glucocorticoid deficiency  
C. Congenital adrenocortical hyperplasia  
D. Adrenal hemorrhage  
E. Congenital HIV infection and adrenal insufficiency  

answer on page 30
Computer-based medical records hold promise for improving treatment and efficiency, but experts say they are open to attack from hackers, malware, and even nosy employees.

The electronic health record (EHR) programs certified for use in medical practices and hospitals are far from secure, but the behavior of many practitioners exacerbates the risks.

"In terms of security management, the healthcare industry is particularly bad," said Avi Rubin, PhD, professor of computer science at Johns Hopkins University and technical director of its Information Security Institute.

Studies have found EHR software surprisingly vulnerable to potential hackers. A research team that examined a pair of EHR systems found very basic vulnerabilities, said team leader Laurie Williams, PhD, a computer science professor at North Carolina State University. The programs were open to "almost beginner level security attacks."

Williams said that these vulnerabilities are not unusual compared with other kinds of software, but are troubling because the records contain such sensitive and personal information. Williams said that if credit card information is breached, a user can close an account and get a new credit card. "But with health records, if someone’s private information gets out, you can’t withdraw that knowledge," she said.

Potential problems range from identity theft from the release of information such as Social Security numbers to tampering with records themselves. "You could possibly change someone’s blood type and then they’d get a transfusion of the wrong type,” she said.

EHR software users are at the mercy of the software developers and government regulators because they must buy a certified system, and Williams and Rubin agreed that the certification process has not paid adequate attention to security. They said that practitioners should pressure vendors and government regulators to make security a higher priority.

"... with health records, if someone’s private information gets out, you can’t withdraw that knowledge.”
— Laurie Williams, computer science professor, North Carolina State University

**10 TIPS FOR IMPROVING PRACTICES** in the Small Healthcare Environment

The U.S. Department of Health and Human Services’ cybersecurity website recommends the following:

- Use strong passwords and change them regularly.
- Keep anti-virus software current.
- Use a firewall, preferably a hardware firewall between a local area network and the Internet.
- Control access so that protected health information is accessible only to people who need to know it.
- Control physical access. The most common way protected health information is compromised is through the loss or theft of devices that contain it, including portable storage media, laptops, and handhelds.
- Limit network access, including operating wireless routers in encrypted mode.
- Plan for the unexpected by creating backups and having a data recovery plan.
- Maintain good computer habits, including uninstalling any nonessential software and keeping software up-to-date with security patches and new features.
- Protect mobile devices from physical theft and signal theft. Encrypt any information they contain.
- Establish a culture in which everyone takes security as seriously as practices like handwashing and disinfection.

For more information, visit [www.healthit.gov/providers-professionals/cybersecurity](http://www.healthit.gov/providers-professionals/cybersecurity).
People Problems
Rubin toured hospitals to observe their practices and was appalled to find a general disregard for computer security. He often saw passwords posted on computers by sticky notes. In one hospital, a nurse had the job of typing a physician’s password into computers so the physician would not time out, which left the machines unattended and unprotected most of the time. The common practice of distributing to patients disks containing their X-rays—and executable programs for reading them—is dangerous because practitioners have no idea what is really on them when patients walk in with them. The disks could contain malware that could infect whole systems.

Williams noted that in the interest of making the transition to electronic records easier, some practices have been tempted to take shortcuts such as having a single log-in ID for doctors and another for nurses, rather than having individual user IDs. “If they do that, they will have no way to trace who did what. So to use the blood example again, they should be able to go back and see who changed the blood type,” Williams said.

Tips for Improvement
Apparently, hackers have not set their sights on the medical establishment in a big way yet—most healthcare security breaches have resulted from mistakes such as the loss or theft of laptops. Rubin recommended engaging a security professional as a consultant or in-house in the case of larger institutions.

—Seaborg is a freelance writer in Charlottesville, VA, and a regular contributor to Endocrine News

Endocrine Press An Imprint of the Endocrine Society

Great ideas are only useful when you share them, so consider publishing your book with Endocrine Press: Endocrine Society’s newly revamped book publishing program.

We are currently soliciting book proposals that provide important and cutting-edge information on a range of issues related to endocrinology.

We are particularly interested in books with scopes and subject matter relative to the Endocrine Society’s mission of advancing excellence in endocrinology to promote its essential and integrative role in scientific discovery, medical practice, and human health.

Key topics of interest include the following:
- Adrenal
- Bone & Calcium
- Cardio Metabolic
- Diabetes
- Lipids & Obesity
- Neuroendocrinology
- Pediatric Endocrinology
- Pituitary
- Reproductive
- Thyroid

SPECIAL CALL FOR MANUSCRIPTS ON HEALTH DISPARITIES IN ENDOCRINE DISORDERS

Submit a book proposal or pitch your own topic by contacting Maxine Aldred at maldred@endocrine.org. For more information about Endocrine Press, please visit http://www.endocrine.org/endocrine-press.
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society


The workgroup reconfirmed previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research.

Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers with Radioiodine-Avoidant Distant Metastases


Radioiodine-metastatic FCDTC are overrepresented with RAS mutations, whereas RAI refractory metastatic thyroid cancers are enriched with BRAF mutations.

Approach to the Patient With Hypogonadotropic Hypogonadism

Leticia Ferreira, Gontijo Silveira, and Ana Claudia Latronico

The precise and early diagnosis of HH can prevent negative physical and psychological sequelae, preserve normal peak bone mass, and restore the fertility in affected patients.

The Effect of Obesity on the Relationship Between Serum Parathyroid Hormone and 25-Hydroxyvitamin D in Women

Sue A. Shapses, Esther J. Lee, Deeptha Sukumar, Ramon Durazo-Arvizu, and Stephen H. Schneider

These results suggest that if PTH is suppressed at a lower serum 25OHD in the obese compared to the entire population, the lower average 25OHD concentrations in the obese may not have the same physiological significance as in the general population.

Approach to Testing Growth Hormone (GH) Secretion in Obese Subjects

Vera Popovic

GH stimulation tests should be avoided in obese subjects with very low pretest probability.

Increased Bone Mass in Mice Lacking the Adipokine Apelin

Lañita Wattanachanyua, Wei-Dar Lu, Ramendra K. Kundu, Liping Wang, Marcia J. Abbott, Dylan O’Carroll, Thomas Quertermous, and Robert A. Nissenson

The increased bone mass in mice lacking apelin suggested complex direct and paracrine/endocrine effects of apelin on bone, possibly via modulating insulin sensitivity. These results indicate that apelin functions as a physiologically significant anti-anabolic factor in bone in vivo.

Renal Protective Effects of Toll-like Receptor 4 Signaling Blockade in Type 2 Diabetic Mice


Treatment improves insulin resistance and protects against the renal injury that occurs in type 2 diabetic nephropathy through both metabolic and antiglomerulosclerotic mechanisms, which suggests that TLR pathway inhibition might play a direct protective role in diabetic kidney disease.

cAMP-Responsive Element Binding Protein: A Vital Link in Embryonic Hormonal Adaptation

Maria Schindler, Sínine Fischer, René Thieme, Bernd Fischer, and Anne Navarrete Santos

Embryonic CREB/ATFs act as insulin/IGF sensors. Lack of insulin is compensated by a CREB-mediated adiponectin expression, which may maintain glucose uptake in blastocysts grown in diabetic mothers.

Age Increase of Estrogen Receptor-α (ERα) in Cortical Astrocytes Impairs Neurotrophic Support in Male and Female Rats

Jason M. Arimoto, Angela Wong, Irina Rozovsky, Sharon W. Lin, Todd E. Morgan, and Caleb E. Finch

The persistent effects of ovarian acyclicity in vitro are hypothesized to arise from steroidal perturbations during ovarian senescence, which suggests that increased astrocyte ERα expression during aging contributes to the E2 desensitization of the neuronal responses in both sexes.

Estrogen-Related Receptor γ (ERRγ) Regulates Oxygen-Dependent Expression of Voltage-gated Potassium (K+) Channels and Tissue Kallikrein during Human Trophoblast Differentiation

Yanmin Luo, Premlata Kumar, and Carole R. Mendelson

ERRγ mediates O2-dependent expression of genes involved in human trophoblast differentiation, function, and vascular homeostasis.
Is there a topic that you would like to learn more about at ENDO?

THE 2014 ANNUAL MEETING STEERING COMMITTEE
welcomes suggestions for the joint 16th International Congress of Endocrinology/The Endocrine Society’s 96th Annual Meeting & Expo

To submit suggestions, visit www.ice-endo2014.org. The deadline to submit suggestions is July 24, 2013.

Introducing THE 2014 ANNUAL MEETING STEERING COMMITTEE!

The 2014 Annual Meeting Steering Committee (AMSC) will have the large task of planning the joint 16th International Congress of Endocrinology/The Endocrine Society’s 96th Annual Meeting & Expo. President Teresa Woodruff, PhD, will work with the chairs and AMSC members to create an exciting and comprehensive program. The first clinician-in-practice chair, Carol Wysham, MD, PhD, will bring special attention to the interests of the practicing clinician members of the Society.

<table>
<thead>
<tr>
<th>Matthew Ringel, MD, PhD</th>
<th>Derek Leroith, MD, PhD, ENDO 2014 Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Science Chair</td>
<td>Kristy Brown, PhD</td>
</tr>
<tr>
<td>Kevin Grove, PhD</td>
<td>Stephanie Lee, MD, PhD</td>
</tr>
<tr>
<td>Basic Science Chair</td>
<td>Gal Omry, MD</td>
</tr>
<tr>
<td>Carol Wysham, MD, PhD</td>
<td>Wiebke Arlt, MD, DSc, FRCP, FMedSci</td>
</tr>
<tr>
<td>Clinician-in-Practice Chair</td>
<td>Gregory Brent, MD</td>
</tr>
<tr>
<td>Richard Eastell, MBBS, MD</td>
<td>Laura Calvi, MD</td>
</tr>
<tr>
<td>Michael Levine, MD</td>
<td>Cheri Deal, MD, PhD</td>
</tr>
<tr>
<td>Steven Smith, MD</td>
<td>Patricia Elizalde, PhD</td>
</tr>
<tr>
<td>Jane Reusch, MD</td>
<td>Ghada Fuleihan, MD, MPH</td>
</tr>
<tr>
<td>Bernard Robaire, PhD</td>
<td>Ashley Grossman, MD, FRCP</td>
</tr>
<tr>
<td>Erica Elizabeth Marsh, MD</td>
<td>Annette Gruters, MD, PhD</td>
</tr>
<tr>
<td>Jorma Toppari, MD, PhD</td>
<td>Robert Handa, PhD</td>
</tr>
<tr>
<td>Nelly Mauras, MD</td>
<td>Anthony Hollenberg, MD</td>
</tr>
<tr>
<td>Adrian Lee, PhD</td>
<td>Malcolm Low, MD, PhD</td>
</tr>
<tr>
<td>Louis Luttrell, MD, PhD</td>
<td>Christopher McCartney, MD</td>
</tr>
<tr>
<td>John Cidlowski, PhD</td>
<td>Robert Millar, PhD</td>
</tr>
<tr>
<td></td>
<td>Sue Moenter, PhD</td>
</tr>
<tr>
<td></td>
<td>John Newell-Price, MD, PhD, MRCP</td>
</tr>
<tr>
<td></td>
<td>Pere Puigserver, PhD</td>
</tr>
<tr>
<td></td>
<td>Elliot Rayfield, MD</td>
</tr>
<tr>
<td></td>
<td>Charles Roberts, Jr, PhD</td>
</tr>
<tr>
<td></td>
<td>Donald Simonson, MD, MPH, ScD</td>
</tr>
<tr>
<td></td>
<td>Frances Sladek, PhD</td>
</tr>
<tr>
<td></td>
<td>Jenny Visser, PhD</td>
</tr>
<tr>
<td></td>
<td>Humphrey Yao, PhD</td>
</tr>
<tr>
<td></td>
<td>Philip Zeitler, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Daniel Marks, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>In addition, eight members of the</td>
</tr>
<tr>
<td></td>
<td>International Society for Endocrinol-</td>
</tr>
<tr>
<td></td>
<td>ogy will be joining the AMSC this year.</td>
</tr>
<tr>
<td></td>
<td>Peter Ebling, MBBS,MD</td>
</tr>
<tr>
<td></td>
<td>Teresa Sir Petermann, MD</td>
</tr>
<tr>
<td></td>
<td>Weiqing Wang, MD</td>
</tr>
<tr>
<td></td>
<td>Philippe Chanson, MD, MS</td>
</tr>
<tr>
<td></td>
<td>Subhanker Chowdhury, MD, MS</td>
</tr>
<tr>
<td></td>
<td>Moines Mercado, MD</td>
</tr>
<tr>
<td></td>
<td>Augustine Ohwovorile, MD, MS</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Paz-Pacheco, BS, MD</td>
</tr>
</tbody>
</table>
The American Board of Pediatrics (ABP) has begun transitioning toward the new “continuous” Maintenance of Certification (MOC) model, requiring physicians to earn 40 Part 2 MOC points per five-year MOC cycle. To address this increased regulatory need, Pediatric ESAP 2013–2014 has been redesigned and ABP-approved to offer 40 MOC Part 2 points, which is twice the number of MOC Part 2 points offered by its predecessor, Pediatric ESAP 2011–2012. This new offering, developed by the Pediatric Self-Assessment Committee, includes two 50-question interactive modules and a printed book. Learn more about the benefits of Pediatric ESAP 2013–2014 on endoselfassessment.org.

ENDOCRINE SOCIETY and HORMONE HEALTH NETWORK Launch New Websites

Visit the new websites of The Endocrine Society and the Hormone Health Network for an improved user experience, including new designs and improved layouts, to help you find the information you need, fast.

The Society website, endocrine.org, provides you with all of the tools and information you need to succeed in your work environment. Log on and stay up-to-date on important events; find products, services, and meetings to help advance your work; learn about hot topics in public policy; and more.

Created for patients, backed by the Society’s clinical and scientific expertise, hormone.org is your partner in endocrine patient education. With more than 100 free resources in English and Spanish, hormone.org educates patients and improves communication. Visited by 2 million people a year, The Hormone Health Network gives your patients a better understanding of hormone, health, disease, and treatment. The Network’s goal is to help providers move patients from educated to engaged, creating active partners in their healthcare.

Submit Your Nominations for the 2013 EARLY INVESTIGATORS WORKSHOP

Did you know that The Endocrine Society annually hosts a workshop specifically designed to provide young investigators an in-depth introduction into the foundation for building successful careers in research at the Early Investigators Workshop? The two-day workshop offers early career investigators career development talks, small group presentations, and networking opportunities with peers and faculty. This year, the Society will hold the Early Investigators Workshop on October 21–22 in Indianapolis, Ind. This workshop is a must-attend for clinical fellows and post-doctoral fellows planning for independent research careers.

Here’s what participants of the 2012 Early Investigators Workshop shared with Endocrine News about their experiences.

Dr. Michael Stitzel, senior post-doctoral fellow at The Johns Hopkins University School of Medicine, was drawn to the workshop by the basic science offerings and sessions focusing on grant writing, lab management, negotiation, and mock study section: “I was expecting two intense days of scientific and professional advice and I was not disappointed. The personal and professional experiences that the faculty advisors shared were enlightening. I left San Francisco with a much better perspective of the “black box” of Study Section and scientific review of grants and with eyes wide open to the challenges and techniques in negotiating for a faculty position.”

He shared additional insights into the workshop’s networking opportunities: “Networking opportunities are usually difficult to facilitate in such a short, two-day workshop,
but I felt the organizers, and particularly the participating faculty, made this a goal. I have found at other meetings that it can be difficult to penetrate the cliques that naturally occur. At this meeting, the faculty did a great job distributing themselves at meals and during the break amongst the trainees. I don’t know if this was a conscious effort, but I did greatly appreciate it! Networking with other fellows who are at the same or similar stages of their careers was an added bonus."

Dr. Irina Bancos, fellow from Mayo Clinic, shared her perspective on the workshop: “I would highly recommend the Early Investigators Workshop to my colleagues! My advice would be to consider presenting a proposal that is in the early stages of development as it is most likely to be thought-provoking to attendees. I also believe that first-year fellows would highly benefit from the workshop as this experience is likely to teach a better way to design research and avoid mistakes. Insightful and motivating!”

Dr. Justin Gregory, pediatric endocrine fellow at Vanderbilt University, also joined in the discussion: “I was given some great suggestions for my research after I gave a short presentation about what I am doing in the lab right now. One helpful suggestion was to look into some surgical literature that I had not considered looking into that has some applicability for my research in hypoglycemia in T1DM. During some of the talks, the speakers had some great words of advice about how to effectively write research grant proposals. I am applying these as I write my F32 grant application. I also really appreciated the insights shared by the speakers about effective time management and balancing life as a physician and as a spouse and parent.”

Registration for the Early Investigators Workshop is now open to post-doctoral and clinical fellows wishing to grow their research knowledge base and develop skills that will help further their research careers. Registration will be open through August 19, 2013. Space for this event is limited so apply today!

For more information, please visit the 2013 Early Investigators Workshop website, www.endocrine.org/awards/ConfTravelGrants/clinical_investigators_workshop/index.cfm.
The answer is:
D. Adrenal hemorrhage

This patient has adrenal calcifications (see arrows) caused by adrenal hemorrhage (Answer D), a well-recognized obstetric complication of the newborn, which is an increasingly rare cause of adrenal insufficiency because of the improvements in care during labor and delivery.

However, it is still an issue, and unless diagnosed and treated early, it can lead to chronic, partially compensated adrenal insufficiency or adrenal insufficiency crisis or both. In about half of the reported cases, the bleeds are bilateral and occur at birth. Gradually, the affected glands develop calcifications. Risk factors include large birth weight, hypoxia, septicemia, coagulation defects, and thromboembolism. Other causes of adrenal calcifications include tuberculosis; autoimmunity; Wolman disease (familial xanthomatosis); Niemann-Pick disease; and masses including hemorrhagic and teratomatous cysts, ganglioneuromas, pheochromocytomas, neuroblastomas, and adrenocortical cancer. Adrenal calcification may also be an incidental finding, although then it is also attributed to perinatal adrenal hemorrhage. This patient’s history and presentation are consistent with the cases with adrenal hemorrhage that have been described in the literature, with presentation of adrenal insufficiency not at birth or shortly thereafter, but rather later in the second or third year of life. Typically, these patients compensate for their adrenal dysfunction with high ACTH levels. Partial adrenal insufficiency should be suspected in any infant who has failure to thrive and difficulty feeding, but no primary gastrointestinal disorder. Their condition may decompensate during an infection, a bout of diarrhea, or the course of any other illness, and then they present with severe adrenal insufficiency like the child in this vignette.

Patients with Allgrove syndrome (Answer A) (also known as triple A syndrome) present with alacrima, achalasia, and adrenal insufficiency, but they never develop calcifications in their adrenal glands.

Allgrove syndrome and other causes of familial glucocorticoid deficiency syndromes (Answer B) also rarely cause mineralocorticoid deficiency.

Congenital adrenocortical hyperplasia (CAH) (Answer C) associated with mineralocorticoid deficiency is an unlikely diagnosis in a fully virilized male with low 17-hydroxyprogesterone levels. Although salt-losing 21-hydroxylase deficiency would be consistent with the biochemical profile in this male toddler, the 17-hydroxyprogesterone levels would be expected to be high. Also, CAH is not known to be associated with adrenal gland calcifications.

Finally, congenital HIV infection (Answer E) can cause adrenal insufficiency, but unless it leads to tuberculosis or parasitic infections (i.e., histoplasmosis), it would not be associated with adrenal gland calcifications. These calcifications tend to also be unilateral in patients who develop them secondary to an infection.
Pediatric Endocrine Board Review (2009-2010) is a distinct resource with 290 questions and detailed answers designed for fellows and clinicians preparing for certification or recertification. Earn up to 12.0 AMA PRA Category 1 Credits™.

Nonmembers: $190  
Members: $150  
In-Training Members: $115

To order visit, www.endo-society.org/store

Pediatric ESAP keeps your pediatric endocrinology expertise up-to-date with 100 clinical case vignettes and multiple-choice questions to sharpen your knowledge and evaluate your ability to diagnose and treat pediatric patients. Pediatric ESAP includes an online interactive module and printed book. Earn up to 32.0 AMA PRA Category 1 Credits™.

Nonmembers: $350  
Members: $250  
In-Training Members: $199

To order visit, www.endoselfassessment.org

Register Now!  
September 24-25, 2013  
Pediatric Endocrine Board Review  
Hyatt Regency New Orleans  
New Orleans, LA  
For more information visit, www.endo-society.org/PEBR
Deliver the best care to your patients with the recently updated, comprehensive collection of evidence-based clinical guidelines. Organized by topic, this single volume includes 20 guidelines with consistent, appropriate health care decisions for specific clinical circumstances. The full list of guidelines can be found below.

Nonmember: $79  
Member: $65  
In-Training Member: $50

**Contents**

**Current Clinical Practice Guidelines**
- Adult Growth Hormone Deficiency
- Continuous Glucose Monitoring
- Hyperglycemia/Insulin Therapy
- Hyperprolactinemia
- Osteoporosis in Men
- Pituitary Incidentaloma
- Thyroid Dysfunction during Pregnancy
- Vitamin D Deficiency
- Hypertriglyceridemia

**Previously Published Clinical Practice Guidelines**
- Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient
- Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency
- Testosterone Therapy in Men with Androgen Deficiency Syndrome (Updated)
- Evaluation and Management of Adult Hypoglycemic Disorders
- Endocrine Treatment of Transsexual Persons
- Evaluation and Treatment of Adult Growth Hormone Deficiency
- Androgen Therapy in Women
- Management of Thyroid Dysfunction during Pregnancy and Postpartum
- Evaluation and Treatment of Hirsutism in Premenopausal Women
- The Diagnosis of Cushing’s Syndrome
- Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism
- Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk
- Prevention and Treatment of Pediatric Obesity

The first endocrine-specific Practice Improvement Module (PIM) is a Web-based, self-evaluation tool designed to assist you in evaluating your care of patients with thyroid nodules. Using data from your practice, including patient charts, our PIM allows you to:

1) Evaluate your performance in evaluating thyroid nodules;
2) Compare your performance to ATA and AACE/AME/ETA clinical guidelines through personalized reports;
3) Create and implement an individualized improvement plan; and
4) Reassess the impact of that improvement plan on your practice.

Complete the PIM, either individually or as a part of a practice team, and earn 20 points toward the Self-Evaluation of Practice Performance (Part 4) requirement of Maintenance of Certification (MOC) and claim up to 20 AMA PRA Category 1 Credits™.

Evaluation of Thyroid Nodules PIM Task Force
Erik Alexander, MD | Carol Greenlee, MD, FACP, FACE | Susan Mandel, MD, MPH

For more information, visit endoselfassessment.org.
PATIENTS EXPECT HEALTH CARE PROVIDERS TO KNOW THE BEST TREATMENT

Optimize patient care with The Endocrine Society’s Clinical Practice Guidelines. You can rely on the Society’s evidence-based, high quality clinical practice guidelines to help improve both health care quality and health outcomes.

Recently published Clinical Practice Guidelines include:

- Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting (January 2012)
- Osteoporosis in Men (June 2012)
- Management of Thyroid Dysfunction During Pregnancy and Postpartum (August 2012)
- Evaluation and Treatment of Hypertriglyceridemia (September 2012)

PRICE PER TITLE: Nonmembers: $15 | Members: $10 | In-Training Members: $10

For more information or to view all Clinical Practice Guidelines, visit store.endo-society.org
Your Partner in Patient Education

The Hormone Health Network joins Society members, health care professionals, patients, and the public in meaningful, informed discussions about hormones and health. Available in both English and Spanish, the Network’s bilingual fact sheet series provides patients with accurate, expert-reviewed information on more than 80 endocrine-related topics in an easy-to-understand format.

Visit www.hormone.org and sign up for Hormone Hotline, our monthly e-update, to get the latest news on Hormone Health Network publications and events.

Together, we can move patients from educated to engaged, from informed to active partners in their healthcare.

Engaging and educating more than 2 million people each year!
Prepare to Pass with the

2012 Endocrine Board Review Online

2012 EBR Online is an interactive online mock exam of 280 case-based questions designed to help fellows and practitioners prepare for certification or recertification. EBR Online features:

- Ability to benchmark your performance against your colleagues
- Comprehensive assessment of your clinical knowledge and areas for improvement
- Thorough review on topic-specific areas, based on the ABIM’s Endocrinology, Diabetes, and Metabolism Certification Examination
- Complimentary copy of Endocrine Board Review 4th Edition*, the perfect print companion and a proven leader in board review curricula.

Earn up to 20.0 AMA PRA Category 1 Credits™.

Nonmember: $445.00
Member: $395.00
In-Training Member: $275.00

For more information and to purchase 2012 EBR Online visit endosessions.org.

*Endocrine Board Review 4th Edition may also be purchased separately at www.endo-society.org/store.
Looking to Improve Your Diagnostic Skills?

NEW!
From Endocrine Press
Unravel puzzling cases of common disorders in our popular primer edited by Leonard Wartofsky, MD. These four-color volumes deliver an entertaining format to improve your clinical knowledge of rare disorders and unusual presentations of common endocrine disorders.

Nonmember Price: $99
Member Price: $79
In-Training Member Price: $65

Buy both and save more than 20%!
Bundle Price:
Nonmember Price: $179
Member Price: $139
In-Training Member Price: $100

To order visit The Endocrine Society’s online store: www.endocrine.org/store.
The Endocrine Society is seeking candidates for the position of Editor-in-Chief of the Journal of Endocrinology & Metabolism (JCEM) for a 5-year term beginning January 1, 2015. Applicants will have an opportunity to work with an outstanding editorial team to direct the world’s leading peer-reviewed journal for clinical research and practice reviews in endocrinology.

All members of The Endocrine Society are encouraged to suggest the names of potential candidates by contacting Scott Herman, Group Managing Editor – Associate Director, Publications for The Endocrine Society, at sherman@endocrine.org. Please submit your suggestions by August 30, 2013.

For more information, visit www.endocrine.org/jcemeic
Visit JCEM Focus to Get the Best Information on Diabetes and Thyroid

Stay Focused with New Microsites from JCEM

Visit the microsites, of the Journal of Clinical Endocrinology & Metabolism (JCEM), Diabetes Focus and Thyroid Focus and maximize your time with free, direct access to in-depth, topic-specific information collected from articles published in JCEM.

Simply visit jcem.endojournals.org and click Diabetes Focus, Thyroid Focus, or Bone/Calcium Focus to find information relevant to your area of interest.

New microsites from Endocrinology, Endocrine Reviews, and Molecular Endocrinology will also be launching soon.
If you are interested in submitting classified advertising to *Endocrine News*, please contact Christine Whorton at endocareers@endocrine.org or 800-361-3906.

**OCHSNER HEALTH SYSTEM in New Orleans** is searching for a **BC/BE ENDOCRINOLOGIST** to join our staff at Ochsner Baptist Medical Center. Candidates with experience or directly from training are welcomed to apply. Areas of interest should include general endocrine disorders, diabetes, and endocrine disorders as related to pregnancy. This position is mainly outpatient based, but will serve a large Ob/Gyn group with significant inpatient consultation. Salary is competitive and commensurate with experience and training.

Ochsner Baptist Medical Center, with a deep-rooted history in Uptown New Orleans, is a fully accredited, full-service hospital staffed by more than 390 physicians. We have all private rooms, an ICU, 13 operating rooms, and a state-of-the-art imaging center. We are proud to be distinguished by our excellence in specialty care and high patient satisfaction scores. Our newly renovated 24-hour full-service emergency department is staffed by a team of board-certified ER physicians.

The Ochsner Health System comprises 8 hospitals and more than 38 clinics across southeast Louisiana with over 1.5 million clinic patient visits annually. Ochsner is a major provider of graduate medical education with 23 ACGME-accredited residency and fellowship programs, including our Endocrinology Fellowship Program. Please visit our Web site at www.ochsner.org.

New Orleans is a cosmopolitan, historic city with a pleasant climate, unique architecture, multiple medical schools and academic centers, professional sports teams, world-class dining and cultural interests, and world-renowned live entertainment and music.

Please email CV to: proffirecruiting@ochsner.org. Ref. # ABENDO1 or call 800-488-2240 for more information. EOE.
In keeping with the mission to advance excellence in endocrinology, The Endocrine Society is pleased to announce the launch of Endocrine Press. This newly revamped publishing program will offer a wide scope of content, from peer-reviewed journals to scholarly books and other material, in both print and digital formats.

Do You Have an Idea for a Book?

A great idea is only useful if you share it. By publishing with Endocrine Press, your knowledge can reach a broad audience of endocrinology professionals and beyond. We’re currently seeking editors, authors, and manuscript ideas.

If you are interested in getting published we can help you get started. Visit www.endocrinepress.org to complete a book proposal form or learn more about the submission process.

Be sure to include the following information in your proposal submission:

- A brief description of the proposed book
- Target audience
- A list of other published works on the same topic and a description of what makes your book unique or different
- Anticipated completion date of the manuscript
- Curriculum vitae or resume and contact information

For additional information, please contact:
Maxine Aldred, maldred@endocrine.org

Learn more at www.endocrinepress.org
WHAT IS A GOITER?
A goiter is an enlarged thyroid gland. The thyroid gland, located in the front of your neck, makes thyroid hormones. When your thyroid gland is enlarged, it can produce too much, too little, or just enough thyroid hormone.

WHAT DO THYROID HORMONES DO?
Thyroid hormones travel from your thyroid gland through the blood to all parts of your body. They control how your body uses food for energy, and help all your organs work well. Thyroid hormones affect your metabolism rate, which means how fast or slow your brain, heart, muscles, liver, and other parts of your body work.

If your metabolism is too fast or too slow, you won’t feel well. For example, if you don’t have enough thyroid hormone and your metabolism slows down, you might feel tired and cold. Or, if you have too much thyroid hormone, you might feel nervous and warm.

DID YOU KNOW?
The most common cause of goiter outside of the U.S. is a lack of iodine in the diet. Iodine is a substance in food (iodized salt and seafood) that the thyroid uses to make thyroid hormones. However, a lack of iodine is not common in the U.S. because iodine is added to salt and many foods.

WHAT ARE THE SYMPTOMS OF A GOITER?
You can have a goiter but have no symptoms at all, other than having some swelling at the base of your neck. Some people also may have

- Tightness in the throat
- Coughing
- Hoarseness
- Trouble swallowing
- Trouble breathing
DEFINITIONS OF THYROID CONDITIONS

**Underactive thyroid gland:** when the thyroid gland doesn’t make enough thyroid hormone; also called hypothyroidism. When the thyroid is underactive, the body’s metabolism runs too slowly.

**Overactive thyroid gland:** when the thyroid gland makes too much thyroid hormone; also called hyperthyroidism. When the thyroid is overactive, metabolism runs too quickly.

**Hashimoto’s disease** (the most common cause of underactive thyroid): when the immune system attacks and damages the thyroid gland; then the damaged gland no longer makes enough thyroid hormone.

**Graves’ disease** (the most common cause of overactive thyroid): when the immune system attacks the thyroid gland and causes it to make too much thyroid hormone.

WHAT CAUSES A GOITER?

In the U.S., the most common causes of swelling are

- Hashimoto’s disease (leading to an underactive thyroid)
- Graves’ disease (leading to an overactive thyroid)
- Nodules (lumps) on one or both sides of the thyroid gland

Less common causes include a hormone made during pregnancy that increases thyroid hormone production, inflammation of the thyroid, or thyroid cancer. A goiter also can be present in a newborn if his or her thyroid gland doesn’t work properly before birth.

WHAT FACTORS INCREASE THE RISK OF A GOITER?

Risk factors include

- Being a woman
- Being over age 40
- Being pregnant or in menopause
- Having a family history of autoimmune disease or goiter
- Having been exposed to radiation as a child or having had radiation treatment to your neck or chest
- Having a diet low in iodine

Some medicines also increase the risk of goiter.

HOW IS A GOITER DIAGNOSED?

A goiter is often found during a physical exam when your doctor feels swelling in your neck. Your doctor also may use other tests to find the cause of the goiter and to see how advanced it is, such as

- Hormone tests to show whether your thyroid gland is underactive or overactive
- Antibody tests for Hashimoto’s disease and Graves’ disease
- Ultrasound to see the size of your thyroid and whether there are nodules
- A thyroid scan to look at your thyroid, especially if your thyroid is overactive
- Other scans (CT or MRI) of the neck to check your windpipe
- A biopsy (using a needle to get a sample of your thyroid for testing)

WHAT IS THE TREATMENT FOR A GOITER?

Treatment depends on the cause of the goiter, its size, and your symptoms. If your goiter is small and your thyroid gland makes normal amounts of thyroid hormone, your doctor might observe the goiter over time instead of starting treatment right away.

Possible treatments include

- Medicines for underactive or overactive thyroid
- Radioactive iodine for overactive thyroid (to shrink the goiter)

Surgery is rarely used. However, removal of the thyroid gland might be recommended for a large goiter, for one causing breathing or swallowing problems, for nodules, or for thyroid cancer.

Questions to ask your doctor

- What is causing my goiter?
- What are my options for treatment?
- What are the risks and benefits of each treatment option?
- How long will I need treatment?
- Should I see an endocrinologist for my care?

RESOURCES

- Find-an-Endocrinologist: www.hormone.org or call 1-800-HORMONE (1-800-467-6663)
- Hormone Health Network information about thyroid disorders: www.hormone.org/Thyroid/overview.cfm
- Mayo Clinic information about goiter: www.mayoclinic.com/health/goiter/DS00217

EDITORS

Bryan Haugen, MD
James Hennessey, MD
Leonard Wartofsky, MD

January 2013

The Hormone Health Network offers free, online resources based on the most advanced clinical and scientific knowledge from The Endocrine Society (www.endo-society.org). The Network’s goal is to move patients from educated to engaged, from informed to active partners in their health care. This fact sheet is also available in Spanish at www.hormone.org/Spanish.
Don’t gamble with your patients’ health.

24 blood glucose meters failed recent accuracy studies.*

Is theirs one of them?

ACCU-CHEK® meters passed every study, every time.
All other major manufacturers had a meter that failed.

Make the switch today.

The recent failure of a large number of blood glucose meters to consistently meet accuracy standards has created growing concern, especially for those using meters to determine how much insulin to dose. Your patients’ health is very important to us. It’s time to switch to an ACCU-CHEK meter today.

For more information, go to accu-chek.com/accurate


ACCU-CHEK NANO and ACCU-CHEK AVIVA are trademarks of Roche.
© 2013 Roche. 316-52547-0613